The vial is supposed to contain lyophilized protein but it appears to be empty. Is there anything in it?

Pellets can be dislodged during shipping and become disbursed on the vial wall and in the cap. Centrifuge or tap the vial on the benchtop to return this material to the vial bottom. If this does not reveal a pellet, closely inspect the cone of the vial. Some pellets appear as only a tiny amount of material or as a transparent film due to the original buffer formulation. This is a normal appearance for many proteins. For example, if the product is originally lyophilized from a solvent such as acetonitrile or ethanol, and supplied carrier-free, you may not be able to detect the pellet with the naked eye. This does not mean the vial is empty. Reconstitute the vial as directed. After reconstitution, protein concentration can be tested with a spectrophotometer.

What is the recommended method for reconstitution of a lyophilized protein or antibody?

Unless more specific directions are on the Certificate of Analysis provided with the product, we suggest the following procedure to ensure optimal recovery: 1. Allow the vial and reconstitution buffer to equilibrate to room temperature. 2. Briefly centrifuge the vial to ensure that all lyophiliate is collected at the bottom of the vial. 3. Add the amount of buffer required to achieve the concentration recommended on the product insert. 4. Allow the vial to reconstitute for 15-30 minutes at room temperature with gentle agitation, like on a rocker platform or rotating by hand. Avoid vigorous shaking that can cause foaming and protein denaturation. 5. Aliquot into volumes greater than 20 μL and store as indicated on the product insert. If the vial exhibits flakes or particulates, mix the product for a couple of hours at room temperature and then at 4oC overnight. Contact Technical Service if product does not go into solution.

Are R&D Systems recombinant proteins and antibodies sterile?

Although the vials are bottled using aseptic techniques, heat-treated vials, and sterile stock solutions, they are not considered or guaranteed to be sterile. If sterile material is needed for an experiment, the material can be filtered through a 0.2 micron filter designed for use with biological fluids.

Do you have a human IgG1 Fc region that would be a suitable negative control for the linker sequence and Fc region in Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF (Catalog # 156-B7)?

Yes, we offer Recombinant Human IgG1 Fc Protein, CF (Catalog # 110-HG), which contains the human IgG Fc region and linker sequence.

Has Recombinant Human PD-L1/B7-H1 Fc Chimera Protein (Catalog # 156-B7), been evaluated on primary cells?

Bioactivity of Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF (Catalog # 156-B7) is evaluated by its ability to inhibit anti-CD3 antibody induced IL-2 secretion in human T lymphocyte primary cells. The ED50 for this effect is 0.075-0.75 μg/mL. We recommend reviewing our list of publications under the Citations tab on the product-specific web page to find reported use of our products in similar experimental layouts.

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF

Name: Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
Brand: rnd
SKU: 156-B7
Rating: 5 (21 reviews)

Catalog # 156-B7

Citations (15)

(21)

Datasheet / COA / SDS

Order Information

Bio-Techne Corporation

tel: (800) 343-7475 (free phone)

tel: (612) 379-2956

customercare.na@bio-techne.com

Shipping Information

$35 to United States

Products in stock will be shipped in 1-3 business days unless specified.

View Distributors

R&D Systems Guarantee

We offer a 100% guarantee on all our products.

Learn More »

Key Product Details

Source:	NS0
Accession #:	Q9NZQ7
Structure / Form:	Disulfide-linked homodimer
Applications:	Bioactivity

View Full Technical Details for Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF

Complete Your Research

Product Specifications

Source

Mouse myeloma cell line, NS0-derived human PD-L1/B7-H1 protein

Human PD-L1 (Phe19-Thr239) Accession # Q9NZQ7	DIEGRMD	Human IgG₁ (Pro100-Lys330)
N-terminus		C-terminus

Purity

>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin level

<0.01 EU per 1 μg of the protein by the LAL method.

N-terminal sequence Analysis

Phe19

Predicted Molecular Mass

52 kDa (monomer)

SDS-PAGE

70-75 kDa, reducing conditions

Activity

Measured by its ability to inhibit anti-CD3 antibody induced IL-2 secretion in human T lymphocytes. The ED₅₀ for this effect is 0.075-0.75 μg/mL.

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF Scientific Data Examples

	Bioactivity of PD-L1 Protein Recombinant Human PD-L1 / B7-H1 Fc Chimera (Catalog # 156-B7) inhibits anti-CD3 antibody-induced IL-2 secretion in human T lymphocytes. The ED₅₀for this effect is 0.075-0.75 µg/mL in the presence of Goat Anti-Human IgG Fc Polyclonal Antibody (Catalog # G-102-C).

Formulation, Preparation and Storage

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

156-B7

Formulation	Lyophilized from a 0.2 μm filtered solution in PBS and NaCl.
Reconstitution	Reconstitute at 100 μg/mL in sterile PBS. Reconstitution Buffer Available: Size / Price Qty Loading... RB01:
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Background: PD-L1/B7-H1

PD-L1, also known as B7-H1, is one of the ligands for PD-1 and plays a critical role in the regulation of T cell immunity (1-6). The PD-1:PD-L1 interaction initiates a negative signaling cascade in T cells leading to inhibition of T cell activation (2,5,7,8). PD-L1 provides a molecular stop signal to the adaptive immune system helping to distinguish between self and foreign antigens. PD-L1 also plays a role in the development of immune tolerance by promoting T cell anergy (1,5) and enhancing regulatory T cell development (8). In addition, PD-L1 favors the development of anti-inflammatory IL-10 and IL-22 producing dendritic cells (7,9) and inhibits the development of Th17 cells (8). Many cancers exhibit upregulated PD-L1 protein expression, and several cancers with high levels of PD-L1 have been associated with increased tumor aggressiveness and poor prognosis. Using new therapeutics that block the PD-L1:PD-1 interaction has proven successful in the clinic for many cancer types and has sparked great interest in the field of cancer immunotherapy.

The PD-L1 protein is an approximately 65 kDa transmembrane glycoprotein belonging to the B7 family of immune regulatory molecules (10). Mature human PD-L1 protein consists of a 220 amino acid (aa) extracellular domain (ECD) with two immunoglobulin-like domains, a 21 aa transmembrane segment, and a 31 aa cytoplasmic domain (11). Within the ECD, human PD-L1 shares 73% and 74% aa sequence identity with mouse and rat B7-H1, respectively. Alternative splicing generates additional isoforms that either lack the first Ig-like domain or are truncated within the second Ig-like domain (12). PD-L1 is expressed on inflammatory-activated immune cells including macrophages, T cells, and B cells (10,13,14,16), keratinocytes (9,11), endothelial and intestinal epithelial cells (2,9), as well as a variety of carcinomas and melanoma (12,16).

Item	Value
References	Tsushima, F. et al. (2007) Blood 110:180. Mazanet, M.M. and C.C.W. Hughes (2002) J. Immunol. 169:3581. Azuma, T. et al. (2008) Blood 111:3635. Butte, M.J. et al. (2008) Mol. Immunol. 45:3567. Park, J.-J. et al. (2010) Blood 116:1291. Ritprajak, P. et al. (2010) J. Immunol. 184:4918. Chen, L. et al. (2007) J. Immunol. 178:6634. Herold, M. et al. (2015) J. Immunol. 195:3584. Scandiuzzi, L. et al. (2014) Cell Rep. 6:625. Ceeraz, S. et al. (2013) Trends Immunol. 34:556. Dong, H. et al. (1999) Nat. Med. 5:1365. Frigola, X. et al. (2011) Clin. Cancer Res. 17:1915. Tamura, H. et al. (2001) Blood 97:1809. Kuang, D.-M. et al. (2014) J. Clin. Invest. 124:4657. Cao, Y. et al. (2010) Cancer Res. 71:1235. Dong, H. et al. (2002) Nat. Med. 8:793.
Long Name	Programmed Death Ligand 1
Entrez Gene IDs	29126 (Human); 60533 (Mouse); 499342 (Rat); 574058 (Porcine); 484186 (Canine); 102145573 (Cynomolgus Monkey)
Alternate Names	Avelumab, B7-H, B7-H1, B7H1, B7H1PDCD1L1, CD274, CD274 antigenMGC142294, CD274 molecule, PD-L1, PD-L1B7 homolog 1, PDCD1L1, PDCD1LG1, PDCD1LG1MGC142296, PDL1, PDL1PDCD1 ligand 1, Programmed death ligand 1, programmed cell death 1 ligand 1

Citations (15)

Showing 1 - 10 of 15 citations Showing All

Filter By:

Search Title:

Citations are publications that use Bio-Techne products. Selected citations for Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF include:

Species: Human
Sample Types: Whole Cells
Applications: Bioassay

L Sun et al. (2020), Targeting glycosylated PD-1 induces potent anti-tumor immunity Cancer Res., 0(0):.
PMID: 32156778
Species: Human
Sample Types: Recombinant Protein
Applications: Bioassay

JK Fierle et al. (2019), Integrating SpyCatcher/SpyTag covalent fusion technology into phage display workflows for rapid antibody discovery Sci Rep, 9(1):12815.
PMID: 31492910
W Fu et al. (2019), CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity Nat Commun, 10(1):4355.
PMID: 31554797
Species: Human
Sample Types: Whole Cells
Applications: Bioassay

KJ Carpenter et al. (2019), LXR-inverse agonism stimulates immune-mediated tumor destruction by enhancing CD8 T-cell activity in triple negative breast cancer Sci Rep, 9(1):19530.
PMID: 31863071
Species: Yeast
Sample Types: Whole Cell

B Cembrola et al. (2019), Rapid Affinity Maturation of Novel Anti-PD-L1 Antibodies by a Fast Drop of the Antigen Concentration and FACS Selection of Yeast Libraries Biomed Res Int, 2019(0):6051870.
PMID: 31976323
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry

A Osa et al. (2018), Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients JCI Insight, 3(19):.
PMID: 30282824
Species: N/A
Sample Types: Protein
Applications: Bioassay

E Burova et al. (2017), Characterization of the anti-PD-1 antibody REGN2810 and its antitumor activity in human PD-1 knock-in mice Mol. Cancer Ther, 0(0):.
PMID: 28265006
Applications: ELISA (Standard)

UM Vogl et al. (2017), Evaluation of Prognostic Immune Signatures in Patients with Breast, Colorectal and Pancreatic Cancer Receiving Chemotherapy Anticancer Res., 37(4):1947-1955.
PMID: 28373465
Species: Human
Sample Types: Protein
Applications: ELISA (Standard)

(2016), B7-H1 antibodies lose antitumor activity due to activation of p38 MAPK that leads to apoptosis of tumor-reactive CD8(+) T cells Sci Rep, 6(0):36722.
PMID: 27824138
Applications: Bioassay

Robert L Ferris (2016), Tumor-infiltrating Tim-3(+) T cells proliferate avidly except when PD-1 is co-expressed: Evidence for intracellular cross talk Oncoimmunology, 5(10):e1200778.
PMID: 27853635
Species: Human
Sample Types: Whole Cells
Applications: Bioassay

Li J et al. (2015), PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment. Cancer Res, 75(3):508-18.
PMID: 25480946
Species: Human
Sample Types: Serum
Applications: ELISA (Standard)

Melendreras S et al. (2014), Soluble co-signaling molecules predict long-term graft outcome in kidney-transplanted patients. PLoS ONE, 9(12):e113396.
PMID: 25478957
Species: Human
Sample Types: Whole Cells
Applications: Bioassay

Chinnadurai R et al. (2014), IDO-independent suppression of T cell effector function by IFN-gamma-licensed human mesenchymal stromal cells. J Immunol, 192(4):1491-501.
PMID: 24403533
Species: Human
Sample Types: Whole Cells
Applications: Bioassay

Steidl C et al. (2011), MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature, 471(7338):377-81.
PMID: 21368758
Wan B et al. (2006), Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis. J. Immunol., 177(12):8844-50.
PMID: 17142787

There are no citations that match your criteria.

Showing 1 - 10 of 15 citations Showing All

Customer Reviews (21)

4.9 out of 5

21 customer ratings

5 stars

90%

4 stars

3 stars

2 stars

1 star

Customer Images

Showing 1 - 5 of 21 reviews Showing All

Filter By:

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF

Name: Anonymous

Application: Binding assay/Protein-protein interaction

Reason for Rating: Tested binding of PDL1-Fc w/ PD-1 using Octet. KD ~1.5uM

Verified Customer | Posted 06/19/2020
Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF

Name: Anonymous

Application: Binding assay/Protein-protein interaction

Verified Customer | Posted 11/15/2019

HEK cells expressing mCherry alone (LEFT) or hPD-1 mCherry (RIGHT) were incubated with 0.25 ug of hPD-L1 hIgG1. Binding was monitored by flow cytometry using an anti-human 488 secondary antibody.
Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF

Name: Anonymous

Application: Stem/Immune cell maintenance or differentiation

Verified Customer | Posted 12/06/2018
Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF

Name: Anonymous

Application: Cell Adhesion

Verified Customer | Posted 10/24/2018
Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF

Name: Anonymous

Application: Enzymatic activity in vitro

Verified Customer | Posted 10/12/2018
Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF

Name: Anonymous

Application: CellProlif

Verified Customer | Posted 09/28/2018
Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF

Name: Anonymous

Application: Binding assay/Protein-protein interaction

Verified Customer | Posted 08/26/2018
Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF

Name: Anonymous

Application: SDS-PAGE Control

Verified Customer | Posted 04/12/2018
Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF

Name: Anonymous

Application: Binding assay/Protein-protein interaction

Verified Customer | Posted 03/30/2018
Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF

Name: Anonymous

Application: SDS-PAGE Control

Verified Customer | Posted 03/15/2018
Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF

Name: Anonymous

Application: SDS-PAGE Control

Verified Customer | Posted 03/11/2018
Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF

Name: Anonymous

Application: Binding assay/Protein-protein interaction

Reason for Rating: Binding observed.

Verified Customer | Posted 02/07/2018
Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF

Name: Anonymous

Application: Binding assay/Protein-protein interaction

Verified Customer | Posted 12/18/2017
Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF

Name: Anonymous

Application: Binding assay/Protein-protein interaction

Verified Customer | Posted 12/06/2017
Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF

Name: Anonymous

Application: Binding assay/Protein-protein interaction

Verified Customer | Posted 12/01/2017
Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF

Name: Anonymous

Application: Binding assay/Protein-protein interaction

Verified Customer | Posted 11/27/2017
Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF

Name: Anonymous

Application: Binding assay/Protein-protein interaction

Verified Customer | Posted 11/18/2017
Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF

Name: Anonymous

Application: Binding assay/Protein-protein interaction

Verified Customer | Posted 07/20/2017
Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF

Name: Anonymous

Application: Cell Adhesion

Verified Customer | Posted 07/20/2017
Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF

Name: Anonymous

Application: SPR assay for Kinetics between PDL-1 and AntiPDL-1 Antibody

Verified Customer | Posted 07/14/2017

SPR experiment
Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF

Name: Anonymous

Verified Customer | Posted 05/23/2017

Using Octet, we tested the ability of B7-H1/PD-L1 to bind recombinant PD-1 (R&D 8986-PD-100) and found them to specifically bind to each other.

There are no reviews that match your criteria.

Showing 1 - 5 of 21 reviews Showing All

FAQs

The vial is supposed to contain lyophilized protein but it appears to be empty. Is there anything in it?

Pellets can be dislodged during shipping and become disbursed on the vial wall and in the cap. Centrifuge or tap the vial on the benchtop to return this material to the vial bottom. If this does not reveal a pellet, closely inspect the cone of the vial. Some pellets appear as only a tiny amount of material or as a transparent film due to the original buffer formulation. This is a normal appearance for many proteins. For example, if the product is originally lyophilized from a solvent such as acetonitrile or ethanol, and supplied carrier-free, you may not be able to detect the pellet with the naked eye. This does not mean the vial is empty. Reconstitute the vial as directed. After reconstitution, protein concentration can be tested with a spectrophotometer.
What is the recommended method for reconstitution of a lyophilized protein or antibody?

Unless more specific directions are on the Certificate of Analysis provided with the product, we suggest the following procedure to ensure optimal recovery: 1. Allow the vial and reconstitution buffer to equilibrate to room temperature. 2. Briefly centrifuge the vial to ensure that all lyophiliate is collected at the bottom of the vial. 3. Add the amount of buffer required to achieve the concentration recommended on the product insert. 4. Allow the vial to reconstitute for 15-30 minutes at room temperature with gentle agitation, like on a rocker platform or rotating by hand. Avoid vigorous shaking that can cause foaming and protein denaturation. 5. Aliquot into volumes greater than 20 μL and store as indicated on the product insert. If the vial exhibits flakes or particulates, mix the product for a couple of hours at room temperature and then at 4^oC overnight. Contact Technical Service if product does not go into solution.
Are R&D Systems recombinant proteins and antibodies sterile?

Although the vials are bottled using aseptic techniques, heat-treated vials, and sterile stock solutions, they are not considered or guaranteed to be sterile. If sterile material is needed for an experiment, the material can be filtered through a 0.2 micron filter designed for use with biological fluids.
What is the pI (Isoelectric Point) of Recombinant Human PD-L1/B7-H1 Fc Chimera Protein (Catalog # 156-B7)?

The calculated pI for Recombinant Human PD-L1/B7-H1 Fc Chimera Protein (Catalog # 156-B7) is 7.1.
Do you have a human IgG1 Fc region that would be a suitable negative control for the linker sequence and Fc region in Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF (Catalog # 156-B7)?

Yes, we offer Recombinant Human IgG1 Fc Protein, CF (Catalog # 110-HG), which contains the human IgG Fc region and linker sequence.
Has Recombinant Human PD-L1/B7-H1 Fc Chimera Protein (Catalog # 156-B7), been evaluated on primary cells?

Bioactivity of Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF (Catalog # 156-B7) is evaluated by its ability to inhibit anti-CD3 antibody induced IL-2 secretion in human T lymphocyte primary cells. The ED50 for this effect is 0.075-0.75 μg/mL. We recommend reviewing our list of publications under the Citations tab on the product-specific web page to find reported use of our products in similar experimental layouts.

Product Datasheets

Download Product Datasheets

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF

Order Information

Shipping Information

R&D Systems Guarantee

Key Product Details

Complete Your Research

Complete Your Experiment

Product Specifications

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF Scientific Data Examples

Formulation, Preparation and Storage

Carrier Free

Reconstitution Calculator

Background: PD-L1/B7-H1

Citations (15)

Customer Reviews (21)

Customer Images

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF

FAQs

Product Datasheets

Product Datasheets

COA

Certificate of Analysis

SDS

Bio-Techne Brands